Direct compression of mosapride citrate in a 5 mg immediate-release tablet core is governed by low-dose content-uniformity risk. The API is typically a white to off-white crystalline powder; handling in low-humidity suites below 40% RH is required because moisture uptake can increase punch adhesion and shift blend flow. A pre-blend of the API with 500 µm-screened spray-dried lactose monohydrate and microcrystalline cellulose is prepared in a bin blender at 12–15 rpm for 20–30 minutes. Magnesium stearate is added as a lubricant at 0.5–1.0 wt%; over-lubrication above 1.5 wt% reduces tablet tensile strength and slows dissolution. Compression on a rotary tablet press with 8 mm biconcave tooling is controlled to a hardness of 40–80 N, friability below 0.8% under USP <1216>, and ejection force below the level at which picking or sticking occurs. Content uniformity is evaluated according to USP <905> with an acceptance value of ≤15.0. Dissolution testing follows USP <711> Apparatus 2, 50 rpm, 900 mL of pH 1.2 or pH 6.8 medium selected during development. Wet granulation becomes necessary when direct-compression blend segregation cannot be reduced below a relative standard deviation of 5%; a high-shear granulator with an impeller speed range of 200–400 rpm and a chopper speed of 1500–3000 rpm can bind fine API particles to the diluent mass, but overgranulation produces hard aggregates and dissolution shift. Because the molecule contains a tertiary amine, reducing sugars present a Maillard-reaction boundary; if lactose monohydrate is used, fluid-bed dryer inlet air is kept below 55°C, and non-reducing mannitol-based formulations are preferred when aqueous wet massing exceeds 45°C. All operations follow FDA 21 CFR 210 and 21 CFR 211.

Why Does Particle Size Distribution Shift Friability in Low-Dose Tablet Cores?

In low-dose direct compression, the fraction of fines below 20 µm is the dominant variable controlling both powder-bed packing and interparticulate bonding. If the API is micronized to a D90 below 20 µm, electrostatic adhesion to blender walls, discharge chutes, and the press feed frame increases fill-weight variability; if the API remains as a coarse crystalline fraction with a D90 above 75 µm, dissolution surface area falls and content non-uniformity risk rises because of percolation. Particle size distribution is measured by laser diffraction according to ISO 13320-1:2020 and by sieve analysis according to USP <811> for powder fineness classification. A pilot-scale rotary press equipped with 35 kN precompression and 65 kN main compression force is used to map ejection force across compaction speeds; higher fine-particle fractions increase tablet tensile strength but reduce bulk flow, while higher coarse-particle fractions lower friability resistance because fewer contact points are formed. Published compaction data for mosapride citrate-specific formulations is limited; therefore, excipient placebo runs are used to define the operating window before API is introduced. The critical response is not hardness alone but the ratio of tensile strength to ejection force, because this ratio predicts whether a formulation will survive scale-up from 10 kg pilot batches to production lots above 150 kg.

Encapsulation of mosapride citrate shifts the unit-operation risk profile from compaction mechanics to powder flow, bulk density stability, and fill-weight consistency. The API is dispersed in a dry blend of lactose monohydrate, maize starch, and croscarmellose sodium; the mixture is passed through a 30-mesh screen and loaded into a double-cone blender. Fill weight on an intermittent-motion dosator or auger-based capsule machine requires a loose bulk density in the range of 0.55–0.70 g/mL and a Carr index below 25%; values above this threshold cause erratic capsule fill and require densification or granulation. Hard gelatin or HPMC capsules of size 3 or 4 are selected for low-dose presentation, and the excipient-to-API ratio may exceed 100:1, making blend homogeneity the primary technical hurdle. Sampling for blend uniformity follows USP <905>, and dissolution follows USP <711>. Capsule shells with equilibrium moisture below 10% at 25°C/60% RH reduce brittle fracture on high-speed machines; if HPMC shells are used, pin-hole formation and delayed dissolution in acidic media are evaluated because shell crosslinking under stress can alter the release profile. The filling operation is paused for weight checks every 15 minutes on high-speed lines, and the coefficient of variation for filled capsule weight is held below 3%.

When the Target Profile Is Controlled Release Rather Than Immediate Release

If a controlled-release tablet is required, the dissolution mechanism shifts from disintegration-controlled release to gel-layer diffusion and erosion. Hypromellose matrices based on USP substitution type 2208 or 2910 are screened at polymer loads from 15% to 35% of tablet mass. The matrix hydrates on contact with gastric fluid, forms a gelatinous layer, and retards mosapride release by diffusion of dissolved ionized species through the swollen polymer network. At polymer loads below 15 wt%, erosion may dominate and increase the risk of early dose release; at polymer loads above 35 wt%, tablet dimensions can exceed 10 mm, compromising patient acceptance. Direct compression of hypromellose-matrix tablets on a rotary press requires precompression to remove air and reduce capping; a main compression force of 12–18 kN is commonly evaluated for 9 mm round tooling, and target hardness is typically 80–120 N with friability below 0.3%. Dissolution testing uses USP <711> Apparatus 2 at 50 rpm with sinkers, or Apparatus 1 at 100 rpm when sticking is observed; time points at 1, 4, 8, and 12 hours in pH-shift media from pH 1.2 to pH 6.8 are used to map the release curve. Mosapride citrate may show pH-dependent solubility, so the release profile must be compared in 0.1 N HCl and pH 6.8 phosphate buffer. Published data for mosapride citrate controlled-release matrix systems is limited; release-rate selection therefore requires pharmacokinetic modelling rather than simple dissolution-range adoption.

Sachet Granule Rheology and Dispersion Test Method Alignment

On vertical form-fill-seal sachet lines, the dosing auger responds to granule size distribution, bulk density, and surface moisture. Mosapride citrate granules are usually produced by top-spray fluid-bed granulation or high-shear wet granulation; a binder solution of povidone K30 at 3–5 wt% in purified water is used, and the wet mass is dried to a loss on drying of ≤2.0% measured by USP <731>. The dried granules are sieved to a target range of 150–850 µm; undersized fines below 150 µm segregate during hopper hold time and increase fill-weight variability, while oversized granules above 850 µm can block the auger and tear the sachet film. Angle of repose measured by USP <1174> is kept below 35°, and bulk density is held within a narrow release window of ±5% from the validated set point. A 5 mg mosapride citrate unit dose in a sachet demands the same content-uniformity rigor as tablets; blend uniformity by USP <905> and assay by an HPLC method with a relative standard deviation below 2% are used for batch release. Dispersibility of granules is tested by transferring the contents to 100 mL of water at 25°C and passing the suspension through a 710 µm sieve; residual particles above 710 µm indicate incomplete wetting or overgranulation and require reformulation of the binder level or drying endpoint.

Injectable Formulation Feasibility at pH Below 4.5

For injectable presentation development, the aqueous solubility of mosapride citrate in the neutral pH range is the critical decision gate. If a simple aqueous solution cannot achieve the required API concentration, formulation work proceeds along two axes: acidification with citric acid or acetic acid to a pH below 4.5 to protonate the tertiary amine, or complexation with hydroxypropyl-β-cyclodextrin. The solution is filtered through a 0.22 µm sterilising-grade membrane; particulate matter is controlled by USP <788> and bacterial endotoxins by USP <85>. Terminal sterilisation at 121°C for 15 minutes is evaluated, but thermal degradation products must be identified and controlled according to ICH Q3B; if degradation exceeds the 0.1% reporting threshold for a maximum daily dose of ≤1 g, aseptic filtration may replace terminal sterilisation. Osmolality is adjusted to 270–320 mOsm/kg for intravenous administration, and the pH specification is set within 3.5–4.5 to balance solubility and injection-site tolerance. Elemental impurities are controlled according to ICH Q3D, residual solvents according to USP <467>, and photostability according to ICH Q1B. If the solution is insufficiently stable in aqueous media, lyophilisation is assessed; the lyophilised cake must reconstitute within 2 minutes in water for injection and meet the same particulate and endotoxin limits. The container-closure system is evaluated for extractables and leachables under USP <1663> and USP <1664>. Published data for mosapride citrate injectable dosage forms is limited; no harmonised compendial injection monograph is referenced in the major pharmacopoeias, so the formulation and stability programme must be prospectively defined.